NCT00770562View on ClinicalTrials.gov

A Study Evaluating the Addition of MabThera (Rituximab) to Standard Treatment in Patients With Idiopathic Thrombocytopenic Purpura (ITP)

PHASE3CompletedINTERVENTIONAL

Enrollment

103

Participants

Timeline

Start Date

July 31, 2005

Primary Completion Date

July 31, 2008

Study Completion Date

July 31, 2008

Conditions

Idiopathic Thrombocytopenic Purpura

Interventions

DRUG

rituximab

DRUG

Dexamethasone

Trial Locations (22)

12100

Cuneo

16132

Genova

20162

Milan

25123

Brescia

27100

Pavia

33100

Udine

35128

Padua

37130

Verona

40138

Bologna

42100

Reggio Emilia

48100

Ravenna

53100

Siena

61100

Pesaro

65100

Pescara

70124

Bari

74100

Taranto

80131

Napoli

90146

Palermo

09121

Cagliari

00133

Roma

00161

Roma

00168

Roma

All Listed Sponsors

lead

Hoffmann-La Roche

INDUSTRY

NCT00770562 - A Study Evaluating the Addition of MabThera (Rituximab) to Standard Treatment in Patients With Idiopathic Thrombocytopenic Purpura (ITP) | Biotech Hunter | Biotech Hunter